首页> 外文OA文献 >Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study

【2h】

Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study

机译：类风湿性关节炎患者继续对乙烯虫生物综合（LBEC0101）或从参考的替代赛转换为LBEC0101的长期疗效，安全性和免疫原性：III期多期一题，随机，双盲，并行组研究的开放标签延伸

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Min-Chan Park; Hiroaki Matsuno; Jinseok Kim; Sung-Hwan Park; Sang-Heon Lee; Yong-Beom Park; Yun Jong Lee; Sang-Il Lee; Won Park; Dong Hyuk Sheen; Jung-Yoon Choe; Chan-Bum Choi; Seung-Jae Hong; Chang-Hee Suh; Shin-Seok Lee; Hoon-Suk Cha; Bin Yoo; Jin-Wuk Hur; Geun-Tae Kim; Wan-Hee Yoo; Han Joo Baek; Kichul Shin; Seung Cheol Shim; Hyung-In Yang; Hyun Ah Kim; Kyung-Su Park; In Ah Choi; Jisoo Lee; Masato Tomomitsu; Seonghye Shin; Jiyoon Lee; Yeong Wook Song;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类
入库时间 2022-08-20 21:58:49

相似文献

外文文献

1. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study [J] . Min-Chan Park, Hiroaki Matsuno, Jinseok Kim, Arthritis research & therapy. . 2019,第1期

机译：使用依那西普生物仿制药（LBEC0101）或从参比依那西普改用LBEC0101对类风湿关节炎患者的长期疗效，安全性和免疫原性：III期多中心，随机，双盲，平行组研究的开放标签扩展
2. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study [J] . Min-Chan Park, Hiroaki Matsuno, Jinseok Kim, Arthritis research & therapy. . 2019,第1期

机译：使用依那西普生物仿制药（LBEC0101）或从参比依那西普改用LBEC0101对类风湿关节炎患者的长期疗效，安全性和免疫原性：III期多中心，随机，双盲，平行组研究的开放标签扩展
3. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate [J] . Matsuno Hiroaki, Tomomitsu Masato, Hagino Atsushi, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2018,第4期

机译：III期，多期，双盲，随机，并行群体研究，以评估LBEC0101和涅安普科学版之间的相似性，在有活性类风湿性关节炎患者的疗效和安全性方面，不充分应对甲氨蝶呤
4. Long-term efficacy safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre randomised double-blind parallel-group study [O] . Min-Chan Park, Hiroaki Matsuno, Jinseok Kim, 2019

机译：使用依那西普生物仿制药（LBEC0101）或从参考依那西普转为LBEC0101的类风湿关节炎患者的长期疗效安全性和免疫原性：III期多中心随机双盲平行分组研究的开放标签扩展
5. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study [O] . Janusz Jaworski, Marco Matucci-Cerinic, Hendrik Schulze-Koops, 2019

机译：从参考Etanercept切换到SDZ ETN，依尼易到生物酸，不影响肠道患者中度至重度的类风湿性关节炎患者的疗效，安全性和免疫原性：III期的48周结果，随机，双盲率研究

Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study

著录项

相似文献

相关主题

期刊订阅